Alessandro Bertolini

1.6k total citations · 1 hit paper
22 papers, 760 citations indexed

About

Alessandro Bertolini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Alessandro Bertolini has authored 22 papers receiving a total of 760 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Hematology. Recurrent topics in Alessandro Bertolini's work include Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Alessandro Bertolini is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Alessandro Bertolini collaborates with scholars based in Italy, Switzerland and Japan. Alessandro Bertolini's co-authors include Suresh S. Ramalingam, Yuri Rukazenkov, Manuel Cobo, Caicun Zhou, Byoung Chul Cho, Thanyanan Reungwetwattana, Isamu Okamoto, Natasha B. Leighl, Andy Brown and Astrid McKeown and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and European Journal of Cancer.

In The Last Decade

Alessandro Bertolini

22 papers receiving 745 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

2018 511 citations Thanyanan Reungwetwattana, Kazuhiko Nakagawa et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alessandro Bertolini Italy	11	532	515	124	103	65	22	760
Naoki Furuya Japan	16	590 1.1×	510 1.0×	181 1.5×	72 0.7×	126 1.9×	89	827
Ryo Toyozawa Japan	17	629 1.2×	618 1.2×	182 1.5×	66 0.6×	105 1.6×	89	932
J.-L. Canon Belgium	11	197 0.4×	486 0.9×	93 0.8×	106 1.0×	44 0.7×	22	685
Lambros Vamvakas Greece	17	370 0.7×	597 1.2×	114 0.9×	71 0.7×	164 2.5×	44	759
Arunee Dechaphunkul Thailand	13	520 1.0×	468 0.9×	190 1.5×	152 1.5×	156 2.4×	62	855
Ramón Palmero Spain	14	328 0.6×	384 0.7×	159 1.3×	62 0.6×	79 1.2×	50	646
Marcelo V. Negrão United States	15	449 0.8×	491 1.0×	223 1.8×	49 0.5×	128 2.0×	65	769
Matthew Robson Japan	6	327 0.6×	283 0.5×	236 1.9×	71 0.7×	39 0.6×	13	561
Yukihiro Toi Japan	10	548 1.0×	1.0k 2.0×	109 0.9×	97 0.9×	49 0.8×	36	1.2k
José Manuel Aramendía Spain	14	275 0.5×	326 0.6×	45 0.4×	104 1.0×	60 0.9×	46	587

Countries citing papers authored by Alessandro Bertolini

Since Specialization

Citations

This map shows the geographic impact of Alessandro Bertolini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Bertolini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Bertolini more than expected).

Fields of papers citing papers by Alessandro Bertolini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandro Bertolini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Bertolini. The network helps show where Alessandro Bertolini may publish in the future.

Co-authorship network of co-authors of Alessandro Bertolini

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Bertolini. A scholar is included among the top collaborators of Alessandro Bertolini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Bertolini. Alessandro Bertolini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Conti, Matteo, Giovanna Luchena, Lorenza Bertù, et al.. (2023). Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study. Cancers. 15(13). 3465–3465. 3 indexed citations

Moretto, Roberto, Mirella Giordano, Anello Marcello Poma, et al.. (2021). Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. European Journal of Cancer. 153. 16–26. 3 indexed citations

Reungwetwattana, Thanyanan, Kazuhiko Nakagawa, Byoung Chul Cho, et al.. (2018). CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 36(33). 3290–3297. 511 indexed citations breakdown →

Marinis, Filippo de, Paolo Bidoli, Andrea Luciani, et al.. (2017). EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer. Anticancer Research. 37(5). 2457–2464. 4 indexed citations

Berenato, Rosa, Filippo Pietrantonio, Marta Caporale, et al.. (2016). Open-label, randomized, multicenter, phase II trial designed to compare the efficacy of CAPTEM combination versus FOLFIRI as second line treatment in patients (pts) who have progressed on or after first-line oxaliplatin-containing chemotherapy for advanced, MGMT methylated, RAS mutated colorectal cancer (CRC).. Journal of Clinical Oncology. 34(15_suppl). TPS3635–TPS3635. 1 indexed citations

Pietrantonio, Filippo, Marta Caporale, Rosa Berenato, et al.. (2016). First-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients (pts) with RAS wild-type, metastatic colorectal cancer (mCRC): The VALENTINO study.. Journal of Clinical Oncology. 34(15_suppl). TPS3634–TPS3634. 1 indexed citations

Antonuzzo, Lorenzo, Elisa Giommoni, Davide Pastorelli, et al.. (2015). Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World Journal of Gastroenterology. 21(23). 7281–7288. 10 indexed citations

Ganzinelli, Monica, Eliana Rulli, Elisa Caiola, et al.. (2015). Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Scientific Reports. 5(1). 16331–16331. 11 indexed citations

Bartolomeo, Maria Di, A. Ciarlo, Alessandro Bertolini, et al.. (2015). Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. European Journal of Cancer. 51(4). 473–481. 15 indexed citations

10.

Fagnani, Daniele, V. Filipazzi, Marco Danova, et al.. (2014). Granulocyte Colony-stimulating Factors Used in Clinical Practice: PoloNord Registry-Based Cohort Italian Study. Tumori Journal. 100(5). 491–498. 12 indexed citations

11.

Cortinovis, Diego, Giordano Beretta, Elena Piazza, et al.. (2013). Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey.. PubMed. 99(1). 45–50. 11 indexed citations

12.

Cortinovis, Diego, Giordano Beretta, Elena Piazza, et al.. (2013). Chemotherapy-Induced Anemia and Oncologist Perception on Treatment: Results of a Web-Based Survey. Tumori Journal. 99(1). 45–50. 11 indexed citations

13.

Farina, Gabriella, Flavia Longo, Olga Martelli, et al.. (2011). Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non–Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer. 12(2). 138–141. 13 indexed citations

14.

Celio, Luigi, S. Frustaci, Angela Buonadonna, et al.. (2010). Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Supportive Care in Cancer. 19(8). 1217–1225. 76 indexed citations

15.

Fagnani, Daniele, Alessandro Bertolini, Laura Catena, et al.. (2008). The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters: an observational study. Blood Coagulation & Fibrinolysis. 20(1). 35–40. 3 indexed citations

16.

Ardizzoia, Antonio, Ilaria Colombo, Monica Giordano, et al.. (2008). Epirubicin-vinorelbine intravenous combination followed by oral vinorelbine as first-line treatment in metastatic breast cancer.. PubMed. 93(6). 544–9. 3 indexed citations

17.

Ardizzoia, Antonio, Ilaria Colombo, Monica Giordano, et al.. (2007). Epirubicin-Vinorelbine Intravenous Combination Followed by Oral Vinorelbine as First-Line Treatment in Metastatic Breast Cancer. Tumori Journal. 93(6). 544–549. 4 indexed citations

18.

Ferrari, Silvia, B. Rovati, Camillo Porta, et al.. (2003). Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor. Cancer Immunology Immunotherapy. 52(6). 359–366. 27 indexed citations

19.

Bertolini, Alessandro, et al.. (2001). Acute Cardiotoxicity during Capecitabine Treatment: A Case Report. Tumori Journal. 87(3). 200–206. 35 indexed citations

20.

Cattaneo, María Teresa, C. Sessa, Emanuele Zucca, et al.. (1987). Enzymuria in Carboplatin Nephrotoxicity. Tumori Journal. 73(5). 487–491. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact